IN2012DN02577A - - Google Patents

Download PDF

Info

Publication number: IN2012DN02577A
Authority: IN; India
Prior art keywords: compounds; jak; pyrrolo; inhibitors; preparation
Prior art date: 2009-10-15

Application number

Other languages

English (en)

Inventor

Brad Alan Acker

Susan J Hartmann

Horng-Chih Huang

Eric Jon Jacobsen

Michele Ann Promo

Sergey Gregory Wolfson

Jin Xie

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-15

Filing date

2010-10-01

Publication date

2015-08-28

2010-10-01 Application filed by Pfizer filed Critical Pfizer

2015-08-28 Publication of IN2012DN02577A publication Critical patent/IN2012DN02577A/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Reproductive Health (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IN2577DEN2012 2009-10-15 2010-10-01 IN2012DN02577A (ro)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25203909P	2009-10-15	2009-10-15
PCT/IB2010/054447 WO2011045702A1 (en)	2009-10-15	2010-10-01	Pyrrolo[2,3-d] pyrimidine compounds

Publications (1)

Publication Number	Publication Date
IN2012DN02577A true IN2012DN02577A (ro)	2015-08-28

Family

ID=43413616

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN2577DEN2012 IN2012DN02577A (ro)	2009-10-15	2010-10-01

Country Status (28)

Country	Link
US (1)	US8633206B2 (ro)
EP (1)	EP2488524B1 (ro)
JP (1)	JP5629324B2 (ro)
KR (1)	KR20120083452A (ro)
CN (1)	CN102574860A (ro)
AP (1)	AP2012006192A0 (ro)
AR (1)	AR078635A1 (ro)
AU (1)	AU2010308028A1 (ro)
CA (1)	CA2776028C (ro)
CL (1)	CL2012000795A1 (ro)
CO (1)	CO6531451A2 (ro)
CR (1)	CR20120164A (ro)
CU (1)	CU20120059A7 (ro)
DO (1)	DOP2012000080A (ro)
EA (1)	EA201290147A1 (ro)
EC (1)	ECSP12011855A (ro)
ES (1)	ES2426407T3 (ro)
IL (1)	IL218802A0 (ro)
IN (1)	IN2012DN02577A (ro)
MA (1)	MA33670B1 (ro)
MX (1)	MX2012004379A (ro)
NI (1)	NI201200053A (ro)
PE (1)	PE20121077A1 (ro)
TN (1)	TN2012000146A1 (ro)
TW (1)	TWI398444B (ro)
UY (1)	UY32947A (ro)
WO (1)	WO2011045702A1 (ro)
ZA (1)	ZA201202718B (ro)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2370451B1 (en)	2008-12-02	2016-11-16	Wave Life Sciences Japan, Inc.	Method for the synthesis of phosphorus atom modified nucleic acids
PT2411393E (pt)	2009-03-23	2014-02-21	Glenmark Pharmaceuticals Sa	Derivados de pirimidina-diona fundidos como moduladores de trpa1
SI2411395T1 (sl)	2009-03-23	2013-07-31	Glenmark Pharmaceuticals S.A.	Furopirimidindionski derivati kot TRPA1 modulatorji
WO2011005761A1 (en)	2009-07-06	2011-01-13	Ontorii, Inc	Novel nucleic acid prodrugs and methods use thereof
TW201111385A (en) *	2009-08-27	2011-04-01	Biocryst Pharm Inc	Heterocyclic compounds as janus kinase inhibitors
WO2011075334A1 (en) *	2009-12-18	2011-06-23	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidine compounds
WO2012039448A1 (ja) *	2010-09-24	2012-03-29	株式会社キラルジェン	不斉補助基
CN107365339A (zh)	2011-07-19	2017-11-21	波涛生命科学有限公司	合成官能化核酸的方法
MY166970A (en)	2011-08-12	2018-07-26	Nissan Chemical Ind Ltd	Subtituted pyrrolo [2,3-h][1,6]naphthyridines and compositions thereof as jak inhibitors
AU2013289880B2 (en)	2012-07-13	2018-08-02	Wave Life Sciences Ltd.	Chiral control
RU2677639C2 (ru)	2012-07-13	2019-01-18	Шин Ниппон Биомедикал Лэбораториз, Лтд.	Хиральный адъювант нуклеиновой кислоты
RU2693381C2 (ru)	2012-07-13	2019-07-02	Уэйв Лайф Сайенсес Лтд.	Асимметричная вспомогательная группа
AU2013291721B2 (en) *	2012-07-17	2016-02-25	Glaxosmithkline Intellectual Property (No.2) Limited	Indolecarbonitriles as selective androgen receptor modulators
CN103896946B (zh) *	2012-12-28	2018-04-03	浙江导明医药科技有限公司	用于预防及治疗多种自身免疫疾病的新化合物
EP2951590A1 (en)	2013-02-04	2015-12-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for assaying jak2 activity in red blood cells and uses thereof
JP6248948B2 (ja)	2013-02-08	2017-12-20	日産化学工業株式会社	３環性ピロロピリジン化合物及びｊａｋ阻害剤
ES2713052T3 (es)	2013-02-22	2019-05-17	Pfizer	Combinación de derivados de pirrolo[2,3-d]pirimidina con uno o más agentes adicionales como inhibidores de janus cinasas (JAK)
DK2991988T3 (en) *	2013-05-02	2017-08-21	Hoffmann La Roche	Pyrrolo [2,3-d] pyrimidine derivatives as CB2 receptor agonists
JPWO2015108048A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10144933B2 (en)	2014-01-15	2018-12-04	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108046A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
PL3094728T3 (pl)	2014-01-16	2022-07-04	Wave Life Sciences Ltd.	Projekt chiralny
EP2924026A1 (en)	2014-03-28	2015-09-30	Novartis Tiergesundheit AG	Aminosulfonylmethylcyclohexanes as JAK inhibitors
SG11201608542YA (en)	2014-05-14	2016-11-29	Nissan Chemical Ind Ltd	Tricyclic compound and jak inhibitor
WO2016024185A1 (en)	2014-08-12	2016-02-18	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
RU2699034C1 (ru) *	2016-02-16	2019-09-03	ЗОИТИС СЕРВИСЕЗ ЭлЭлСи	Способ получения соединений 7H-пирроло[2,3-d]пиримидина
CN107098908B (zh) *	2016-02-23	2021-01-08	欣凯医药科技(上海)有限公司	一种吡咯并嘧啶类化合物的制备方法和应用
WO2018167283A1 (en)	2017-03-17	2018-09-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2018189335A1 (en)	2017-04-13	2018-10-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2020092015A1 (en)	2018-11-02	2020-05-07	University Of Rochester	Therapeutic mitigation of epithelial infection
US20220106319A1 (en) *	2019-01-30	2022-04-07	Gargamel (Zhuhai) Biotech Ltd.	Jak inhibitor and preparation method therefor
IL264854A (en) *	2019-02-14	2020-08-31	Bahat Anat	Spt5 inhibitors and methods of use thereof
WO2021003084A1 (en) *	2019-07-01	2021-01-07	Ligang Qian	P2x7r antagonists
CN114761011B (zh) *	2019-08-26	2024-06-14	肯沃斯公司	用作jak1抑制剂的取代的(7h-吡咯并[2,3-d]嘧啶-4-基)氨基化合物
CN115246833B (zh) *	2021-04-27	2024-08-13	洛阳惠中兽药有限公司	一种奥拉替尼化合物及其中间体化合物的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9911365A (pt) *	1998-06-19	2001-03-13	Pfizer Prod Inc	Compostos pirrolo[2,3-d]pirimidina
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
NZ518884A (en)	1999-12-10	2004-02-27	Pfizer Prod Inc	Pyrrolo[2,3-d]pyrimidine compounds
ES2257410T3 (es) *	2000-06-26	2006-08-01	Pfizer Products Inc.	Compuestos de pirrolo(2,3-d)pirimidina como agentes inmunosupresores.
US7301023B2 (en)	2001-05-31	2007-11-27	Pfizer Inc.	Chiral salt resolution
EP1572649A2 (en)	2002-11-21	2005-09-14	Pfizer Products Inc.	3-amino-piperidine derivatives and processes for their preparation
CA2536954C (en) *	2003-08-29	2012-11-27	Exelixis, Inc.	C-kit modulators and methods of use
EP1687309A1 (en)	2003-11-17	2006-08-09	Pfizer Products Inc.	Pyrrolopyrimidine compounds useful in treatment of cancer
CN1926140A (zh)	2004-03-05	2007-03-07	大正制药株式会社	吡咯并嘧啶衍生物
CA2572331A1 (en) *	2004-07-02	2006-02-09	Exelixis, Inc.	C-met modulators and method of use
AR054416A1 (es) *	2004-12-22	2007-06-27	Incyte Corp	Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
JP5225079B2 (ja)	2005-06-08	2013-07-03	ライジェルファーマシューティカルズ，インコーポレイテッド	Ｊａｋ経路の阻害のための組成物および方法
CN102127078A (zh)	2005-07-14	2011-07-20	安斯泰来制药株式会社	Janus激酶3的杂环类抑制剂
SG170783A1 (en)	2005-07-29	2011-05-30	Pfizer Prod Inc	Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
CA2623032A1 (en)	2005-09-30	2007-04-12	Vertex Pharmaceuticals Incorporated	Deazapurines useful as inhibitors of janus kinases
BRPI0618179A2 (pt)	2005-11-01	2011-08-23	Targegen Inc	inibidores de biaril meta pirimidina de cinases
JP2009528295A (ja)	2006-02-24	2009-08-06	ライジェルファーマシューティカルズ，インコーポレイテッド	Ｊａｋ経路の阻害のための組成物および方法
MX2008011127A (es) *	2006-03-02	2008-10-31	Astellas Pharma Inc	INHIBIDOR DE 17ß HSD TIPO 5.
WO2009049028A1 (en)	2007-10-09	2009-04-16	Targegen Inc.	Pyrrolopyrimidine compounds and their use as janus kinase modulators
WO2009115084A2 (de)	2008-03-20	2009-09-24	Schebo Biotech Ag	Neue pyrrolopyrimidin-derivate und deren verwendungen
NZ605292A (en) *	2008-08-20	2014-06-27	Zoetis Services Llc	Pyrrolo[2,3-d]pyrimidine compounds

2010
- 2010-10-01 EP EP10771200.2A patent/EP2488524B1/en active Active
- 2010-10-01 CA CA2776028A patent/CA2776028C/en not_active Expired - Fee Related
- 2010-10-01 JP JP2012533715A patent/JP5629324B2/ja not_active Expired - Fee Related
- 2010-10-01 AU AU2010308028A patent/AU2010308028A1/en not_active Abandoned
- 2010-10-01 CN CN2010800461239A patent/CN102574860A/zh active Pending
- 2010-10-01 PE PE2012000447A patent/PE20121077A1/es not_active Application Discontinuation
- 2010-10-01 ES ES10771200T patent/ES2426407T3/es active Active
- 2010-10-01 EA EA201290147A patent/EA201290147A1/ru unknown
- 2010-10-01 WO PCT/IB2010/054447 patent/WO2011045702A1/en active Application Filing
- 2010-10-01 AP AP2012006192A patent/AP2012006192A0/xx unknown
- 2010-10-01 IN IN2577DEN2012 patent/IN2012DN02577A/en unknown
- 2010-10-01 MX MX2012004379A patent/MX2012004379A/es unknown
- 2010-10-01 KR KR1020127012417A patent/KR20120083452A/ko not_active Application Discontinuation
- 2010-10-12 TW TW099134779A patent/TWI398444B/zh not_active IP Right Cessation
- 2010-10-13 US US12/903,554 patent/US8633206B2/en active Active
- 2010-10-14 AR ARP100103751A patent/AR078635A1/es not_active Application Discontinuation
- 2010-10-15 UY UY0001032947A patent/UY32947A/es not_active Application Discontinuation
2012
- 2012-03-22 IL IL218802A patent/IL218802A0/en unknown
- 2012-03-23 DO DO2012000080A patent/DOP2012000080A/es unknown
- 2012-03-29 TN TNP2012000146A patent/TN2012000146A1/fr unknown
- 2012-03-30 CL CL2012000795A patent/CL2012000795A1/es unknown
- 2012-03-30 CR CR20120164A patent/CR20120164A/es unknown
- 2012-04-09 NI NI201200053A patent/NI201200053A/es unknown
- 2012-04-13 MA MA34774A patent/MA33670B1/fr unknown
- 2012-04-13 ZA ZA2012/02718A patent/ZA201202718B/en unknown
- 2012-04-13 CU CU20120059A patent/CU20120059A7/es unknown
- 2012-04-18 CO CO12064126A patent/CO6531451A2/es not_active Application Discontinuation
- 2012-04-27 EC ECSP12011855 patent/ECSP12011855A/es unknown

Also Published As

Publication number	Publication date
EP2488524A1 (en)	2012-08-22
CA2776028C (en)	2015-12-01
PE20121077A1 (es)	2012-08-10
AP2012006192A0 (en)	2012-04-30
ECSP12011855A (es)	2012-06-29
MX2012004379A (es)	2012-06-01
US20110136765A1 (en)	2011-06-09
JP2013508266A (ja)	2013-03-07
ZA201202718B (en)	2012-12-27
TN2012000146A1 (fr)	2013-09-19
EP2488524B1 (en)	2013-07-03
AU2010308028A1 (en)	2012-04-19
WO2011045702A1 (en)	2011-04-21
EA201290147A1 (ru)	2012-11-30
CA2776028A1 (en)	2011-04-21
IL218802A0 (en)	2012-06-28
TWI398444B (zh)	2013-06-11
UY32947A (es)	2011-05-31
US8633206B2 (en)	2014-01-21
DOP2012000080A (es)	2012-06-15
CN102574860A (zh)	2012-07-11
KR20120083452A (ko)	2012-07-25
TW201125866A (en)	2011-08-01
CR20120164A (es)	2012-11-07
CL2012000795A1 (es)	2012-09-07
AR078635A1 (es)	2011-11-23
CO6531451A2 (es)	2012-09-28
CU20120059A7 (es)	2012-06-29
NI201200053A (es)	2012-08-09
MA33670B1 (fr)	2012-10-01
ES2426407T3 (es)	2013-10-23
JP5629324B2 (ja)	2014-11-19

Publication	Publication Date	Title
IN2012DN02577A (ro)	2015-08-28
MX2012009074A (es)	2012-08-23	Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
ME01269B (me)	2013-06-20	Jedinjenja pirolo (2,3-d) pirimidina
IL278119B (en)	2022-06-01	Disubstituted pyrazolo[5.1–a]pyrimidine compounds as trk kinase inhibitors
PH12015501779A1 (en)	2015-12-02	Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
MX2012007175A (es)	2012-07-04	Derivados de imidazopiridina como inhibidores de jak.
TN2011000245A1 (en)	2012-12-17	Organic compounds
ZA201200982B (en)	2014-07-30	Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
MX363715B (es)	2019-03-29	Formas solidas de un inhbidor de cdk4/6 selectivo.
WO2007067506A3 (en)	2007-08-16	2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
MX2012014017A (es)	2013-04-29	Derivados de heteroaril imidazolona como inhibidores de jak.
PT2658844T (pt)	2017-01-24	Novos derivados de pirimidinas, sua preparação e utilização farmacêutica como inibidores de fosforilação de akt (pkb)
JO2822B1 (en)	2014-09-15	Inhibitors of the enzyme kinase P70 S6 and AKT
TW200745102A (en)	2007-12-16	Pyrido[2,3-d]pyrimidine derivatives, preparation thereof, therapeutic use thereof
CY1115106T1 (el)	2016-12-14	Ενωσεις πυρρολο[2,3-d]πυριμιδινης